drugset
drugset / Trial / NCT01515306

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

NCT01515306 ↗

Phase 2 Completed 48 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate whether there are no clinically significant pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors. Part A of this study will investigate the potential of concomitant ramucirumab (IMC-1121B) to affect the pharmacokinetics of paclitaxel. Part B of this study will investigate the pharmacokinetics of ramucirumab (IMC-1121B) as monotherapy.

Timeline

Start
2012-07-19
Primary completion
2013-03-20
Completion
2021-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 80 mg/m2 Intravenous
Subject Ramucirumab Monoclonal antibody 8 mg/kg Intravenous

Indications

cancer